Skip Navigation


Hum. Reprod. Advance Access originally published online on September 21, 2007
Human Reproduction 2007 22(11):2857-2862; doi:10.1093/humrep/dem275
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow All Versions of this Article:
22/11/2857    most recent
dem275v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Johnson, N.P.
Right arrow Articles by Chamley, L.W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, N.P.
Right arrow Articles by Chamley, L.W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Lipiodol fertility enhancement: two-year follow-up of a randomized trial suggests a transient benefit in endometriosis, but a sustained benefit in unexplained infertility

N.P. Johnson1,2,3,5, R. Kwok1, A.W. Stewart1, M. Saththianathan1, W.E. Hadden4 and L.W. Chamley1

1 Department of Obstetrics and Gynaecology, University of Auckland, Auckland, New Zealand 2 Fertility Plus & National Women’s Health at Auckland Hospital, Auckland, New Zealand 3 Auckland Gynaecology Group, 105 Remuera Road, Auckland, New Zealand 4 Auckland Radiology Group, 641 Manukau Road, Royal Oak, Auckland, New Zealand

5 Correspondence address. Tel: +64-9-3737599; Fax: +64-9-6305579; E-mail: n.johnson{at}auckland.ac.nz

BACKGROUND: A New Zealand randomized trial has shown that lipiodol treatment enhances fertility with high short-term effectiveness for women with endometriosis.

METHODS: An open randomized trial in a single-centre secondary- and tertiary-level infertility service assessing lipiodol flushing versus no intervention. A total of 158 women with unexplained infertility (62 women with mild endometriosis and 96 women with pure unexplained infertility) were evaluated at 24 months after trial entry. The main outcome measure was clinical pregnancy, assessed using a Cox proportional hazards regression model.

RESULTS: There was a significant benefit in overall pregnancy rate following lipiodol [hazard ratio 2.0, 95% confidence interval (CI) 1.3–3.2]. Among women with endometriosis, the benefit in pregnancy rate seen in the first 6 months following lipiodol (hazard ratio 5.4, 95% CI 2.1–14.2) was not present at 6–24 months (hazard ratio 0.6, 95% CI 0.2–2.1). There was a more consistent effect of lipiodol on fertility throughout the 24-month follow-up among women with unexplained infertility (hazard ratio 2.0, 95% CI 1.1–3.5). CONCLUSIONS: Lipiodol flushing is effective at enhancing fertility not only for women with endometriosis, but also for those with pure unexplained infertility.

Key words: endometriosis/lipiodol/oil-soluble contrast media/randomized trial/unexplained infertility

Submitted on January 21, 2007; resubmitted on April 29, 2007; accepted on July 19, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.